Key result
FDA expanded access approves ~99% of single-patient INDs rapidly, challenging the need for right-to-try laws.
Answers are grounded in this paper and cite their sources.
With drug approval times taking an average of 8 years from entry into clinical trials to full U.S. Food and Drug Administration (FDA) approval, patients with life-threatening and severely debilitating disease and no reasonable therapeutic options are advocating for expanded access (EA) to investigational drugs prior to approval. Special investigational new drug (IND) application categories allow patients who meet specific criteria to receive treatment with non-approved drugs. The FDA approves over 99% of all single-patient INDs, providing emergency approval within hours, and non-emergency approval within an average of 4 days. "Right-to-try" laws passed in 38 states would allow patients to bypass FDA processes altogether, but contain controversial provisions that some claim risk more harm than benefit to desperate and vulnerable patients. This review focuses on FDA EA to non-approved drugs through a special category of IND-the single-patient IND-and "right-to-try" (R2T) access outside of the FDA.
No takes yet. Share an insight, caveat, or question.
Gail A. Van Norman (2018) conducted a review in Life-threatening and severely debilitating disease with no reasonable therapeutic options. Expanded access (single-patient IND) and right-to-try access to investigational drugs was evaluated. FDA expanded access approves >99% of single-patient INDs within hours to an average of 4 days, whereas state right-to-try laws bypass the FDA with controversial provisions.
Synapse has enriched 10 related papers. Consider them for comparative context: